SCL Science

SCL Science Rule of 40

The Rule of 40 of SCL Science (246960.KQ) as of Nov 12, 2026 is 351.34 %. In the previous year, Rule of 40 was 182.35 % — a change of 92.68% (higher).

Rule of 40

351.34 %

YoY

92.68%

Last updated:

Rule of 40 of SCL Science is 2025 351.34 % . Rule of 40 of SCL Science was 2024 182.35 % . It decreases by 92.68% higher compared to the previous year.

The SCL Science Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
-352.26 KRW
Jan 1, 2019
-527.81 KRW
Jan 1, 2020
-504.39 KRW
Jan 1, 2021
-911.53 KRW
Jan 1, 2022
-1,455.15 KRW
Jan 1, 2023
-271.00 KRW
Jan 1, 2024
182.35 KRW
Jan 1, 2025
351.34 KRW
The SCL Science Rule of 40 history
YEARRule of 40YoY
351.34 %+92.68%
182.35 %-167.29%
-271.00 %-81.38%
-1,455.15 %+59.64%
-911.53 %+80.72%
-504.39 %-4.44%
-527.81 %+49.83%
-352.26 %-74.38%
-1,375.18 %+23.49%
-1,113.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCL Science Stock analysis

What does SCL Science do? SCL Science Inc, listed on the Korean stock exchange with ticker 246960.KQ and ISIN KR7246960009, is a healthcare company headquartered in Seoul, South Korea. The company went public on February 1, 2019, as indicated by its IPO date. SCL Science Inc operates within the healthcare sector, focusing on the development and commercialization of medical products. According to the provided information, the company manufactures and sells hemostatic medical agents, which are used to control bleeding in medical procedures. The company's products include medical hemostats and sealants that utilize biomimetic technology, a technology inspired by natural biological processes. The company's website is innotherapy.com, which may provide further details about its products and services. SCL Science Inc is based in Seoul, South Korea, and its primary business activities are centered around the healthcare industry, specifically in the field of hemostatic solutions. The company's focus on biomimetic technology suggests an innovative approach to developing medical products that mimic natural biological mechanisms. The company's operations are likely aimed at providing medical professionals with effective tools for managing bleeding during surgical and other medical procedures. The company's market presence is within South Korea, though it may have international reach through its website and product distribution channels. The information provided does not include details on the company's revenue, market share, or specific competitors, nor does it mention any acquisitions or key personnel beyond the general description of its business activities. SCL Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCL Science stock

Rule of 40 of SCL Science is 351.34 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 SCL Science since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — SCL Science

All Key Metrics — SCL Science